CoreWeave announced a new multi-year customer agreement with Harell Data, a biotech AI platform, which will utilize CoreWeave Cloud for its proprietary datasets. Concurrently, UBS initiated coverage with a 'Buy' rating and a $120 price target, citing strong AI computing demand and CoreWeave's undervalued revenue multiple.
CoreWeave (CRWV) is experiencing a significant positive catalyst with two key developments. First, the new multi-year customer agreement with Harell Data, a biotech AI platform, validates CoreWeave's specialized cloud infrastructure for high-demand AI workloads, particularly in a sensitive sector like biotech. This partnership highlights CoreWeave's ability to attract and support cutting-edge AI applications. Second, UBS initiating coverage with a 'Buy' rating and a $120 price target provides a strong vote of confidence from a major financial institution, especially given the analyst's contrarian view against 'Wall Street skepticism' regarding the company's debt load. This could lead to increased institutional interest and a re-evaluation of the stock's valuation, offering a short-term opportunity for price appreciation and long-term validation of its business model, despite existing debt concerns.